Insider Selling: Horizon Therapeutics Public Limited (NASDAQ:HZNP) EVP Sells 20,214 Shares of Stock

Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating) EVP Michael A. Desjardin sold 20,214 shares of the stock in a transaction on Tuesday, April 12th. The shares were sold at an average price of $113.12, for a total transaction of $2,286,607.68. Following the completion of the sale, the executive vice president now owns 82,346 shares of the company’s stock, valued at approximately $9,314,979.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

NASDAQ:HZNP opened at $116.36 on Friday. The firm’s 50 day simple moving average is $102.50 and its 200 day simple moving average is $103.95. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.16 and a quick ratio of 2.90. Horizon Therapeutics Public Limited has a one year low of $83.42 and a one year high of $120.54. The company has a market cap of $26.67 billion, a PE ratio of 52.18, a P/E/G ratio of 1.56 and a beta of 1.12.

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) last posted its earnings results on Tuesday, March 1st. The biopharmaceutical company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.27 by $0.14. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $995.90 million. Horizon Therapeutics Public had a net margin of 16.57% and a return on equity of 26.66%. The firm’s revenue was up 36.1% compared to the same quarter last year. During the same period last year, the company earned $1.28 EPS. Equities research analysts expect that Horizon Therapeutics Public Limited will post 5.81 EPS for the current year.

A number of analysts have commented on HZNP shares. Morgan Stanley increased their price target on shares of Horizon Therapeutics Public from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, March 2nd. Piper Sandler cut their target price on shares of Horizon Therapeutics Public from $143.00 to $133.00 in a research note on Wednesday, January 26th. Oppenheimer assumed coverage on shares of Horizon Therapeutics Public in a research note on Monday, March 14th. They set an “outperform” rating and a $140.00 target price for the company. Wells Fargo & Company restated a “buy” rating and set a $133.00 target price on shares of Horizon Therapeutics Public in a research note on Friday, April 8th. Finally, StockNews.com initiated coverage on shares of Horizon Therapeutics Public in a research report on Thursday, March 31st. They set a “hold” rating on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Horizon Therapeutics Public presently has a consensus rating of “Buy” and an average target price of $133.67.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Bar Harbor Trust Services lifted its position in shares of Horizon Therapeutics Public by 13.2% in the 1st quarter. Bar Harbor Trust Services now owns 27,266 shares of the biopharmaceutical company’s stock worth $2,869,000 after purchasing an additional 3,179 shares during the period. North Growth Management Ltd. acquired a new position in shares of Horizon Therapeutics Public in the 1st quarter worth approximately $12,708,000. Edmonds Duncan Registered Investment Advisors LLC lifted its position in shares of Horizon Therapeutics Public by 6.8% in the 1st quarter. Edmonds Duncan Registered Investment Advisors LLC now owns 2,969 shares of the biopharmaceutical company’s stock worth $312,000 after purchasing an additional 190 shares during the period. Cim LLC lifted its position in shares of Horizon Therapeutics Public by 1.1% in the 1st quarter. Cim LLC now owns 11,492 shares of the biopharmaceutical company’s stock worth $1,293,000 after purchasing an additional 127 shares during the period. Finally, Optimum Investment Advisors acquired a new position in shares of Horizon Therapeutics Public in the 1st quarter worth approximately $124,000. Hedge funds and other institutional investors own 88.11% of the company’s stock.

About Horizon Therapeutics Public (Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Featured Articles

Insider Buying and Selling by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.